- Trusted Product Information
Advancing Global Health Through Scientific Innovation
Driving innovation in medicine through advanced research, precision science, and global pharmaceutical solutions.
Our Trusted Collaborators
Companies across industries rely on our platform to manage their HR operations daily
Smart. Secure. Scientific. Scalable
Trusted Platform for Progress
Every Stage Matters in Saving Lives
Understand each development phase that transforms scientific discovery into safe, effective, and approved medical treatments.
DISCOVERY & PRECLINICAL
REGULATORY OVERVIEW
CLINICAL TRIALS ( PHASE 1 - 3 )
Driven by Science, Committed to Health
Pioneering medical innovation with trusted expertise, global collaboration, and unwavering dedication to patient care.
Cardiovex-101
Target Indication: Hypertension
Development Stage: Hypertension
Cardiovex-101 is an innovative small-molecule therapeutic designed to manage moderate to severe hypertension. This candidate works by selectively inhibiting angiotensin receptors to reduce vascular resistance and improve cardiac output without significantly impacting renal function.
- Currently in Phase II clinical trials, Cardiovex-101 has demonstrated statistically significant reductions in both systolic and diastolic blood pressure across a diverse patient population
- First-in-class mechanism targeting dual pathways of vascular regulation Oral, once-daily formulation for improved patient compliance
- Pending Phase II results, the program is expected to advance to Phase III trials by early next year, focusing on long-term outcomes and broader population efficacy.
From Discovery to Cure, Clearly Tracked
Stay informed with every research phase and milestone on our development journey
01
Discovery Initiation — Q2 2023
Initial compound screening and biomarker identification began for autoimmune disease therapy targeting T-cell modulation.
02
Preclinical Validation — Q4 2023
Initial compound screening and biomarker identification began for autoimmune disease therapy targeting T-cell modulation.
03
Phase I Enrollment — Q1 2024
Initial compound screening and biomarker identification began for autoimmune disease therapy targeting T-cell modulation.
04
Phase III Protocol Finalization — Q3 2025
Completed NDA (New Drug Application) submission to FDA and EMA for respiratory drug RespiraX-22 after successful Phase III trials.Initiated manufacturing scale-up and global distribution strategy for diabetes treatment Glucorin-5, targeting 18 countries by launch.
05
Market Launch Preparation — Q2 2026
Completed NDA (New Drug Application) submission to FDA and EMA for respiratory drug RespiraX-22 after successful Phase III trials.Initiated manufacturing scale-up and global distribution strategy for diabetes treatment Glucorin-5, targeting 18 countries by launch.
Voices of Trust, Powered by Science
Hear real stories from partners, patients, and professionals who’ve experienced our innovation in action.
